The Impact of Losartan on the Lifetime Incidence of End-Stage Renal Disease and Costs in Patients with Type 2 Diabetes and Nephropathy

Author： Carides George W.  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.24, Iss.6, 2006-01, pp. : 549-558

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacokinetics and Blood Pressure Response of Losartan in End-Stage Renal Disease

By Sica D.A.  

Clinical Pharmacokinetics, Vol. 38, Iss. 6, 2000-06 ,pp. : 519-526

Adis International

Access to resources Recommend Favorite

Pharmacokinetics of Rosiglitazone in Patients with End-stage Renal Disease

By Thompson-Culkin K   Zussman B   Miller AK   Freed MI  

The Journal of International Medical Research, Vol. 30, Iss. 4, 2002-07 ,pp. : 391-399

Field House Publishing

Access to resources Recommend Favorite

Pharmacoeconomic aspects of losartan treatment to delay progression of renal disease in patients with Type 2 diabetes

By Postma Maarten J   Kruidhof Hanneke   Berg Lolkje TW de Jong-van den   Zeeuw Dick de  

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 9, 2003-09 ,pp. : 1543-1550

Informa Healthcare

Access to resources Recommend Favorite

Losartan: real benefits in RENAAL disease for patients with type 2 diabetes

By  

Inpharma, Vol. 1, Iss. 1290, 2001-01 ,pp. : 11-12

Adis International

Access to resources Recommend Favorite

Downregulation of Hepatic Carbonyl Reductase Type 1 in End-Stage Renal Disease

By  

Drug Metabolism Letters, Vol. 9, Iss. 2, 2015-08 ,pp. : 111-118

Bentham Science Publishers

Access to resources Recommend Favorite